RELATED PARTIES	6 Months Ended
Jun. 30, 2017
Related Party Transactions [Abstract]
Related Party Transactions	RELATED PARTIES The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture and its diagnostic information services joint ventures, which are accounted for under the equity method of accounting. During the three months ended June 30, 2017 and 2016, the Company recognized net revenues of $11 million and $8 million, respectively, associated with diagnostic information services provided to its equity method investees. During the six months ended June 30, 2017 and 2016, the Company recognized net revenues of $20 million and $16 million, respectively, associated with such services. As of June 30, 2017 and December 31, 2016, there was $13 million and $10 million, respectively, of accounts receivable from equity method investees related to such services. During the three months ended June 30, 2017 and 2016, the Company recognized income of $5 million and $4 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. During each of the six months ended June 30, 2017 and 2016, the Company recognized income of $9 million associated with the performance of such services classified within selling, general and administrative expenses. As of June 30, 2017 and December 31, 2016, there was $14 million and $5 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of June 30, 2017 and December 31, 2016 included $16 million and $9 million, respectively, due to equity method investees.

RELATED PARTIES

The Company's equity method investees primarily consist of its clinical trials central laboratory services joint venture and its diagnostic information services joint ventures, which are accounted for under the equity method of accounting. During the three months ended June 30, 2017 and 2016, the Company recognized net revenues of $11 million and $8 million, respectively, associated with diagnostic information services provided to its equity method investees. During the six months ended June 30, 2017 and 2016, the Company recognized net revenues of $20 million and $16 million, respectively, associated with such services. As of June 30, 2017 and December 31, 2016, there was $13 million and $10 million, respectively, of accounts receivable from equity method investees related to such services.

During the three months ended June 30, 2017 and 2016, the Company recognized income of $5 million and $4 million, respectively, associated with the performance of certain corporate services, including transition services, for its equity method investees, classified within selling, general and administrative expenses. During each of the six months ended June 30, 2017 and 2016, the Company recognized income of $9 million associated with the performance of such services classified within selling, general and administrative expenses. As of June 30, 2017 and December 31, 2016, there was $14 million and $5 million, respectively, of other receivables from equity method investees included in prepaid expenses and other current assets related to these service agreements and other transition related items. In addition, accounts payable and accrued expenses as of June 30, 2017 and December 31, 2016 included $16 million and $9 million, respectively, due to equity method investees.